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We report a rare case of the coexistence of a gastric small cell neuroendocrine carcinoma with a gastric adenocarcinoma. A 62-year-old 
man presented with epigastric soreness for 1 month. Esophagogastroduodenoscopy revealed a Borrmann type I tumor at the lesser cur-
vature of the lower body of the stomach. The patient underwent a distal gastrectomy with D2 lymph node dissection and the resected 
specimen exhibited a 3.5x3.5 cm sized, fungating lesion. Two separated, not intermingling, lesions with non-adenocarcinoma compo-
nents encircled by well differentiated adenocarcinoma components were identified microscopically. The non-adenocarcinoma component 
showed neuroendocrine features, such as a solid and trabecular pattern, and the tumor cells showed a high nuclear grade with minimal 
cytoplasm, indistinct nucleoli, and positive response for synaptophysin, CD56. The final pathological diagnosis was a gastric mixed 
exocrine-endocrine carcinoma (MEEC) composed of an adenocarcinoma and small cell neuroendocrine carcinoma of the collision type. 
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Introduction
The term “mixed exocrine-endocrine carcinoma” (MEEC), 
which is proposed by the W orld Health Organization (WHO) clas-
sification of endocrine tumors, refers to the neoplasm with diver-
gent exocrine and endocrine differentiation, especially originated in 
the pancreas, appendix or stomach.(1) Theses tumors were called 
by different names according to both the extent and the structural 
shape of two components: composite glandular-endocrine carci-
noma, collision tumor, neuroendocrine differentiated adenocarci-
noma, amphicrine tumor, goblet cell carcinoid and so on. 
Nearly all neoplasms that develop in the stomach are adenocar-
cinomas, whereas gastric neuroendocrine tumors (NETs) represent 
less than 1% of all gastric neoplasms. In addition, they account for 
only 2~4% of all gastrointestinal NETs.(2) Most commonly, NETs 
are located at the appendix, ileum, or rectum, where NETs oc-
casionally coexist with adenocarcinoma. However, in the stomach, 
the coexistence of NETSs and adenocarcinoma is rare, and most 
tumors that do coexist are composed of carcinoid or low-grade B-
cell lymphoma and adenocarcinoma.(3,4) W e report here a case of 
MEEC with adenocarcinoma and small cell neuroendocrine carci-
noma. 
Case Report
A 62-year-old man presented with epigastric soreness for 1 
month. Physical examination was unremarkable and laboratory 
findings showed no abnormalities. Esophagogastroduodenoscopy 
revealed a Borrmann type I tumor at the lesser curvature of the 
lower body of the stomach. Contrast-enhanced computed to-
mography (CT) showed a 3 cm sized, elevated mass with regional 
enlarged lymph nodes. The diagnosis, proven from the biopsy 
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specimens taken from the gastric tumor lesion, was poorly dif-
ferentiated carcinoma. The patient underwent distal gastrectomy 
with Billroth II anastomosis and D2 lymph node dissection. The 
resected specimen exhibited a 3.5×3.5 cm sized, Borrmann type 
I lesion at the body of the stomach macroscopically (Fig. 1). Mi-
croscopically, routine hematoxylin-eosin-stained section showed 
two separated, not intermingling, lesions with different histologic 
features under low-power magnification (Fig. 2A). These lesions 
had a characteristic feature with non-adenocarcinoma compo-
nents encircled by well differentiated adenocarcinoma components 
(Fig. 2B). The non-adenocarcinoma component showed a solid, 
organoid, and trabecular pattern, and the tumor cell have a small 
round hyperchromatic nuclei with a high nuclear grade, indistinct 
nucleoli, nuclear molding, and scanty cytoplasm. There was clear 
evidence of necrosis and increased mitotic activity (33/10 HPF) in 
Fig. 1. The resected specimen shows a 3.5×3.5 cm sized, Borrmann 
type I lesion at the gastric body.
Fig. 2. (A) The tumor lesion is composed of two separated and different features (hematoxylin-eosin (H&E) stain, original magnification, ×10). (B) 
A borderline area of small cell neuroendocrine carcinoma and well differentiated adenocarcinoma shows abrupt transition (H&E stain, original 
magnification, ×400). (C) The tumor cells of neuroendocrine carcinoma show a high nuclear grade, indistinct nucleoli, and nuclear molding with 
scanty cytoplasm, and there is increased mitotic activity (H&E stain, original magnification, ×400). (D) The tumor cells of neuroendocrine carci-
noma show positive staining for synaptophysin (synaptophysin, original magnification, ×400).Lee HH, et al.
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the non-adenocarcinoma component (Fig. 2C). On immunohis-
tochemical staining, the tumor cell showed a positive response for 
synaptophysin (Fig. 2D), CD56 and a focally positive response for 
cytokeratin AE1/3. These histopathologic and immunohistochemi-
cal findings of non-adenocarcinoma components were compatible 
with small cell neuroendocrine carcinoma. The small cell neuroen-
docrine carcinoma components and adenocarcinoma components 
accounted for about 65 and 35 percent of tumor lesion, respectively. 
Consequently, this tumor was diagnosed as gastric mixed exocrine-
endocrine carcinoma composed of adenocarcinoma and small cell 
neuroendocrine carcinoma, of collision type.
The final pathologic results revealed poorly differentiated carci-
noma invading the proper muscle with no lymph node metastasis 
(0/40), but each one positive on lymphatic and vascular invasion. 
The patient was diagnosed as stage IB (T2N0M0) according to the 
7th edition of the International Union Against Cancer TNM classi-
fication. Postoperative recovery was uneventful, and the patient was 
discharged on postoperative day 7.
Discussion
In the WHO classification, Gastric NETs are categorized into 
3 groups according to size, rate of proliferation and malignancy: 
well-differentiated tumor (carcinoid) with benign or uncertain be-
havior, well-differentiated neuroendocrine carcinoma (malignant 
carcinoid) with a low grade malignant behavior, and poorly dif-
ferentiated neuroendocrine carcinoma (small cell carcinoma) with 
high grade malignant behavior.(1) In addition to these classifica-
tions, the most recently defined entity of non-small cell NETs with 
high grade malignant behavior tumor is the large cell neuroendo-
crine carcinoma (LCNEC), which is well established in pulmonary 
NETs, but very rarely reported in gastric NETs.(5) In 1993, Rindi 
et al.(6) classified gastric NETs into 3 types base on clinical char-
acteristics. Type 1 is the most frequent (70~80% of all cases) and 
associated with chronic atrophic gastritis. This type of NETs appear 
as small multifocal tumors in most cases. Type 2 is rare and occurs 
in association with Zollinger-Ellison syndrome in multiple endo-
crine neoplasia type 1 (MEN-1). Type 3 is the second most com-
mon and occurs in a sporadic and solitary large form. These tumors 
have a metastasis rate of 10~20% at diagnosis and histologically 
show well to low differentiated carcinomas or even MEECs. 
The spectrum of neuroendocrine and exocrine differentiation 
in the mixed tumor displays variable extent of two components, 
potentially ranging from 1 to 99%, and variable morphological 
patterns, ranging from a single scattered neuroendocrine cell to a 
well-identifiable neuroendocrine tumor cell population. MEECs 
are distinguished from adenocarcinoma with focal neuroendo-
crine differentiation by two major parameters: (1) the extension 
of each component (at least 30%) and (2) the structural feature of 
the neuroendocrine components as well differentiated organoid or 
poorly differentiated solid/diffuse growth patterns.(7) Under the 
condition of “the rule of 30%”, MEECs have two separate features: 
intermingled(composite)-type with haphazard admixture of exo-
crine and endocrine elements within the same tumor mass, and 
the collision type with juxtaposition of both components without 
admixture within the same tumor mass.(8)
Contrary to an adenocarcinoma with focal neuroendocrine dif-
ferentiation, which shows a similar clinical prognosis compared 
to the usual adenocarcinoma,(9) the clinical outcome of MEECs 
follows that of a more aggressive cell type. Therefore, regarding 
recurrence or metastasis of MEECs, the target of treatment is set 
similarly to the more aggressive differentiated tumors. In case of 
MEECs with well-differentiated neuroendocrine components of 
benign or low grade malignant behavior, chemotherapy would be 
focused on exocrine component. In contrast, in those with small 
cell neuroendocrine carcinoma or LCNEC, endocrine component 
wound be the main target of the therapy. 
 The most common primary sites of extrapulmonary small cell 
carcinoma (EPSCC) are the gastrointestinal (GI) tract, the genito-
urinary system, and the head and neck region.(10,11) GI EPSCC 
are usually diagnosed at an advanced stage and at least half are 
diagnosed with distant metastasis. Even when disease is localized, 
however, nearly all patients recur with distant metastasis. The most 
frequent metastatic site is the liver. Consequently, most patients 
with GI EPSCC have a dismal prognosis with a five-year survival 
of less than 15%.(12,13) Rothenstein et al.(14) studied a group of 
patients with GI EPSCC who underwent curative resection with a 
good prognosis, whereas several studies have reported that surgery 
with curative intent should be considered only as part of a mul-
timodality approach for selected patients with limited-stage GI 
EPSCC. The multimodality treatment include adjuvant radiotherapy 
for incompletely resected disease and systemic chemotherapy.(12,15) 
The most commonly used chemotherapeutic combination regimens 
for GI EPSCC are cisplatin/etoposide, carboplatin/etoposide, and 
cisplatin/irinotecan. 
In the present case, although the patient underwent curative sur-
gery and was diagnosed with limited disease (TNM stage IB), the 
tumor consisted of poorly differentiated (small cell) neuroendocrine Mixed Exocrine and Endocrine Carcinoma
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carcinoma and well differentiated tubular adenocarcinoma, as a 
collision type. Therefore, we are planning a close follow up strat-
egy keeping in mind the poor prognosis of small cell carcinoma, 
and the possibility of potential hepatic metastasis. However, after 
discussing with medical oncologists, we decided to defer adjuvant 
chemotherapy considering the early stage of the tumor. 
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